A Monocenter, Open Label Study to Evaluate the Safety and Efficacy of Daratumumab in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Daratumumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Pharmacodynamics
- Acronyms DARALUP
- 15 Jun 2024 Status changed from not yet recruiting to recruiting.
- 15 Jun 2024 Results (n=10) assessing safety and efficacy of daratumumab in moderate to severe SLE presented at the 25th Annual Congress of the European League Against Rheumatism
- 25 Mar 2021 New trial record